Romana Hochreiter, PhD

Director
Valneva GMBH, Austria

Disclosure(s): Valneva Austria GmbH: Employee, owner of stock options, WO2021/207615 A1

Poster(s):

• (P-599) 6-Valent, OspA-Based VLA15 Lyme Disease Vaccine Candidate Against Lyme Borreliosis in a Healthy Pediatric and Adult Study Population: A Phase 2 Study Update
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT